Skip to main content
Erschienen in: Pathology & Oncology Research 2/2019

27.10.2018 | Original Article

Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer

verfasst von: Haochang Hu, Tiangong Wang, Ranran Pan, Yong Yang, Bin Li, Cong Zhou, Jun Zhao, Yi Huang, Shiwei Duan

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is one of the leading causes of death worldwide. Aberrant DNA methylation has been recognized as one of the most common molecular alterations in CRC. The goal of this study was to investigate the diagnostic value of SFRP1 and SFRP2 methylation for CRC. A total of 80 pairs of CRC patients were recruited to test the association of SFRP1 and SFRP2 promotor methylation with CRC. Methylation assay was performed using quantitative methylation-specific polymerase chain reaction (qMSP) method. In this study, we found the methylation levels of SFRP1 and SFRP2 in CRC tumor tissues were significantly higher than those in the adjacent non-tumor tissues (SFRP1: P = 2E-5; SFRP2: P = 0.014). Further bioinformatics analysis of TCGA data confirmed the association of the two genes with CRC (SFRP1: P = 7E-21; SFRP2: P = 5E-24). Luciferase reporter gene assay showed that the recombinant plasmids with SFRP1 and SFRP2 fragments could significantly enhance promoter activity (SFRP1: P = 0.002; SFRP2: P = 0.004). In addition, SFRP1 and SFRP2 methylation were inversely correlated with the mRNA expression displayed by TCGA data mining (SFRP1: r = −0.432, P = 4E-11; SFRP2: r = −0.478, P = 1E-13). GEO data analysis indicated that SFRP1 and SFRP2 expression were increased in three CRC cell lines (COLO320, HCT116 and HT29) after 5′-AZA-deoxycytidine treatment, suggesting that DNA methylation played an important role in regulating gene expression of the two genes. Our results confirmed that promoter methylation of SFRP1 and SFRP2 contributed to the risk of CRC.
Literatur
1.
Zurück zum Zitat Huang J, Tan ZR, Yu J, Li H, Lv QL, Shao YY, Zhou HH (2017) DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma. Onco Targets Ther 10:4739–4751CrossRefPubMedPubMedCentral Huang J, Tan ZR, Yu J, Li H, Lv QL, Shao YY, Zhou HH (2017) DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma. Onco Targets Ther 10:4739–4751CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, Yang P, Chen S, Ye M, Duan S (2017) DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene 630:1–7CrossRefPubMed Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, Yang P, Chen S, Ye M, Duan S (2017) DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene 630:1–7CrossRefPubMed
3.
Zurück zum Zitat Hu H, Chen X, Wang C, Jiang Y, Li J, Ying X et al (2017) The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget 8:84054–84065PubMedPubMedCentral Hu H, Chen X, Wang C, Jiang Y, Li J, Ying X et al (2017) The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget 8:84054–84065PubMedPubMedCentral
4.
Zurück zum Zitat Dashwood RH (1999) Early detection and prevention of colorectal cancer (review). Oncol Rep 6:277–281PubMed Dashwood RH (1999) Early detection and prevention of colorectal cancer (review). Oncol Rep 6:277–281PubMed
5.
Zurück zum Zitat Wu D, Chen X, Xu Y, Wang H, Yu G, Jiang L, Hong Q, Duan S (2017) Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma. Oncol Lett 13:2745–2750CrossRefPubMedPubMedCentral Wu D, Chen X, Xu Y, Wang H, Yu G, Jiang L, Hong Q, Duan S (2017) Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma. Oncol Lett 13:2745–2750CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Liu S, Chen X, Chen R, Wang J, Zhu G, Jiang J et al (2017) Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget 8:36354–36367PubMedPubMedCentral Liu S, Chen X, Chen R, Wang J, Zhu G, Jiang J et al (2017) Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget 8:36354–36367PubMedPubMedCentral
7.
8.
Zurück zum Zitat Piras G, Monne M, Palmas AD, Calvisi A, Asproni R, Vacca F, Pilo L, Gabbas A, Latte G (2014) Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma. Clin Epigenetics 6:16CrossRefPubMedPubMedCentral Piras G, Monne M, Palmas AD, Calvisi A, Asproni R, Vacca F, Pilo L, Gabbas A, Latte G (2014) Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma. Clin Epigenetics 6:16CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F et al (2013) Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol 8:199PubMedPubMedCentral Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F et al (2013) Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol 8:199PubMedPubMedCentral
11.
Zurück zum Zitat Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J (2012) CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res 18:263–270CrossRefPubMed Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J (2012) CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res 18:263–270CrossRefPubMed
12.
Zurück zum Zitat Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S (2017) Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics 9:126CrossRefPubMedPubMedCentral Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S (2017) Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics 9:126CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY, Han ZG (2007) Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7:126CrossRefPubMedPubMedCentral Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY, Han ZG (2007) Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7:126CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E et al (2011) Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama 65:169–177PubMed Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E et al (2011) Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama 65:169–177PubMed
15.
Zurück zum Zitat Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, Choi KY, Kim H, Kim HO, Jeong KU, Chun HK, Kim K, Park DI (2017) Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res 15:495–501CrossRefPubMedPubMedCentral Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, Choi KY, Kim H, Kim HO, Jeong KU, Chun HK, Kim K, Park DI (2017) Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res 15:495–501CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Bartak BK, Kalmar A, Peterfia B, Patai AV, Galamb O, Valcz G et al (2017) Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12:751–763CrossRefPubMedPubMedCentral Bartak BK, Kalmar A, Peterfia B, Patai AV, Galamb O, Valcz G et al (2017) Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12:751–763CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Babaei H, Mohammadi M, Salehi R (2016) DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J 57:242–245CrossRefPubMedPubMedCentral Babaei H, Mohammadi M, Salehi R (2016) DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J 57:242–245CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Zhang H, Zhu YQ, Wu YQ, Zhang P, Qi J (2014) Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol 20:6329–6335CrossRefPubMedPubMedCentral Zhang H, Zhu YQ, Wu YQ, Zhang P, Qi J (2014) Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol 20:6329–6335CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Huang Z, Li L, Wang J (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52:2287–2291CrossRefPubMed Huang Z, Li L, Wang J (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52:2287–2291CrossRefPubMed
20.
Zurück zum Zitat Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883–888CrossRefPubMed Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883–888CrossRefPubMed
21.
Zurück zum Zitat Li B, Chen X, Jiang Y, Yang Y, Zhong J, Zhou C, Hu H, Duan S (2017) CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population. Immunol Lett 190:15–19CrossRefPubMed Li B, Chen X, Jiang Y, Yang Y, Zhong J, Zhou C, Hu H, Duan S (2017) CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population. Immunol Lett 190:15–19CrossRefPubMed
22.
Zurück zum Zitat Cannas V, Daino GL, Corona A, Esposito F, Tramontano E (2015) A luciferase reporter gene assay to measure Ebola virus viral protein 35-associated inhibition of double-stranded RNA-stimulated, retinoic acid-inducible gene 1-mediated induction of interferon beta. J Infect Dis 212(Suppl 2):S277–S281CrossRefPubMed Cannas V, Daino GL, Corona A, Esposito F, Tramontano E (2015) A luciferase reporter gene assay to measure Ebola virus viral protein 35-associated inhibition of double-stranded RNA-stimulated, retinoic acid-inducible gene 1-mediated induction of interferon beta. J Infect Dis 212(Suppl 2):S277–S281CrossRefPubMed
23.
Zurück zum Zitat Yu J, Zhai X, Li X, Zhong C, Guo C, Yang F, Yuan Y, Zheng S (2017) Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci Rep 7:14265CrossRefPubMedPubMedCentral Yu J, Zhai X, Li X, Zhong C, Guo C, Yang F, Yuan Y, Zheng S (2017) Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci Rep 7:14265CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yamashita K, Watanabe M (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195–199CrossRefPubMed Yamashita K, Watanabe M (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195–199CrossRefPubMed
25.
Zurück zum Zitat Li X, Kong L, Liao S, Lu J, Ma L, Long X (2017) The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi J Gastroenterol 23:28–33CrossRefPubMedPubMedCentral Li X, Kong L, Liao S, Lu J, Ma L, Long X (2017) The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi J Gastroenterol 23:28–33CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Wu Y, Gong L, Xu J, Mou Y, Xu X, Qian Z (2017) The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer. Onco Targets Ther 10:5827–5834CrossRefPubMedPubMedCentral Wu Y, Gong L, Xu J, Mou Y, Xu X, Qian Z (2017) The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer. Onco Targets Ther 10:5827–5834CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G (2017) Current and future biomarkers in colorectal cancer. Ann Gastroenterol 30:613–621PubMedPubMedCentral Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G (2017) Current and future biomarkers in colorectal cancer. Ann Gastroenterol 30:613–621PubMedPubMedCentral
28.
Zurück zum Zitat Sugai T, Yoshida M, Eizuka M, Uesugii N, Habano W, Otsuka K, Sasaki A, Yamamoto E, Matsumoto T, Suzuki H (2017) Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clin Epigenetics 9:55CrossRefPubMedPubMedCentral Sugai T, Yoshida M, Eizuka M, Uesugii N, Habano W, Otsuka K, Sasaki A, Yamamoto E, Matsumoto T, Suzuki H (2017) Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clin Epigenetics 9:55CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JKV, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124–1132CrossRefPubMed Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JKV, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124–1132CrossRefPubMed
30.
Zurück zum Zitat Huang S, Zhong X, Gao J, Song R, Wu H, Zi S et al (2014) Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma. Biomed Res Int 2014:256723PubMedPubMedCentral Huang S, Zhong X, Gao J, Song R, Wu H, Zi S et al (2014) Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma. Biomed Res Int 2014:256723PubMedPubMedCentral
31.
Zurück zum Zitat Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, Dahl E (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488CrossRefPubMed Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, Dahl E (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488CrossRefPubMed
32.
Zurück zum Zitat Ba S, Xuan Y, Long ZW, Chen HY, Zheng SS (2017) MicroRNA-27a promotes the proliferation and invasiveness of Colon Cancer cells by targeting SFRP1 through the Wnt/beta-catenin signaling pathway. Cell Physiol Biochem 42:1920–1933CrossRefPubMed Ba S, Xuan Y, Long ZW, Chen HY, Zheng SS (2017) MicroRNA-27a promotes the proliferation and invasiveness of Colon Cancer cells by targeting SFRP1 through the Wnt/beta-catenin signaling pathway. Cell Physiol Biochem 42:1920–1933CrossRefPubMed
33.
Zurück zum Zitat Liu Y, Zhou Q, Zhou D, Huang C, Meng X, Li J (2017) Secreted frizzled-related protein 2-mediated cancer events: Friend or foe? Pharmacol Rep 69:403–8 Liu Y, Zhou Q, Zhou D, Huang C, Meng X, Li J (2017) Secreted frizzled-related protein 2-mediated cancer events: Friend or foe? Pharmacol Rep 69:403–8
34.
Zurück zum Zitat Worm Orntoft MB (2018) Review of blood-based colorectal Cancer screening: how far are circulating cell-free DNA methylation markers from clinical implementation? Clin Colorectal Cancer 17:e415–ee33CrossRefPubMed Worm Orntoft MB (2018) Review of blood-based colorectal Cancer screening: how far are circulating cell-free DNA methylation markers from clinical implementation? Clin Colorectal Cancer 17:e415–ee33CrossRefPubMed
35.
Zurück zum Zitat Harada T, Yamamoto E, Yamano HO, Nojima M, Maruyama R, Kumegawa K, Ashida M, Yoshikawa K, Kimura T, Harada E, Takagi R, Tanaka Y, Aoki H, Nishizono M, Nakaoka M, Tsuyada A, Niinuma T, Kai M, Shimoda K, Shinomura Y, Sugai T, Imai K, Suzuki H (2014) Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer. Cancer Prev Res 7:1002–1010CrossRef Harada T, Yamamoto E, Yamano HO, Nojima M, Maruyama R, Kumegawa K, Ashida M, Yoshikawa K, Kimura T, Harada E, Takagi R, Tanaka Y, Aoki H, Nishizono M, Nakaoka M, Tsuyada A, Niinuma T, Kai M, Shimoda K, Shinomura Y, Sugai T, Imai K, Suzuki H (2014) Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer. Cancer Prev Res 7:1002–1010CrossRef
Metadaten
Titel
Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer
verfasst von
Haochang Hu
Tiangong Wang
Ranran Pan
Yong Yang
Bin Li
Cong Zhou
Jun Zhao
Yi Huang
Shiwei Duan
Publikationsdatum
27.10.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0505-6

Weitere Artikel der Ausgabe 2/2019

Pathology & Oncology Research 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.